Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods.
The authors compared five methods of studying survival bias associated with time-to-treatment initiation in a drug effectiveness study using medical administrative databases (1996-2002) from Quebec, Canada. The first two methods illustrated how survival bias could be introduced. Three additional methods were considered to control for this bias. Methods were compared in the context of evaluating statins for secondary prevention in elderly patients post-acute myocardial infarction who initiated statins within 90 days after discharge and those who did not. Method 1 that classified patients into users and nonusers at discharge resulted in an overestimation of the benefit (38% relative risk reduction at 1 year). In method 2, following users from the time of the first prescription and nonusers from a randomly selected time between 0 and 90 days attenuated the effect toward the null (10% relative risk reduction). Method 3 controlled for survival bias by following patients from the end of the 90-day time window; however, it suffered a major loss of statistical efficiency and precision. Method 4 matched prescription time distribution between users and nonusers at cohort entry. Method 5 used a time-dependent variable for treatment initiation. Methods 4 and 5 better controlled for survival bias and yielded similar results, suggesting a 20% risk reduction of recurrent myocardial infarction or death events.
Zhou
Zheng
Z
Department of Epidemiology and Biostatistics, McGill University, Montréal, Quebec, Canada.
Rahme
Elham
E
Abrahamowicz
Michal
M
Pilote
Louise
L
D000368:Aged; D000369:Aged, 80 and over; D015982:Bias; D015331:Cohort Studies; D004334:Drug Administration Schedule; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality* / Q000517:prevention & control; D010043:Outcome and Process Assessment, Health Care; D011792:Quebec / Q000453:epidemiology; D012189:Retrospective Studies; D055502:Secondary Prevention; D016019:Survival Analysis
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors